SM
Therapeutic Areas
Novartis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cosentyx® | Pediatric Hidradenitis Suppurativa (12+) | Approved |
| Pan-mutant-selective PI3Kα inhibitor | Breast Cancer | Acquisition |
Leadership Team at Novartis
GC
Giovanni Caforio, M.D.
Board Chair
NC
Nancy C. Andrews, M.D., Ph.D.
Board Member
TB
Ton Buechner
Board Member
PB
Patrice Bula
Lead Independent Director
E(
Elizabeth (Liz) Doherty
Board Member
BH
Bridgette Heller
Board Member
FV
Frans van Houten
Board Member
EM
Elizabeth McNally, M.D., Ph.D.
Board Member
AD
Ana de Pro Gonzalo
Board Member
CS
Charles Swanton, M.B.Ph.D.
Board Member